Efficacy and safety of established and off-label ADHD drug therapies for cognitive impairment or attention-deficit hyperactivity disorder symptoms in bipolar disorder: A systematic review by the ISBD Targeting Cognition Task Force

Kamilla W. Miskowiak, Zacharias Obel, Riccardo Gugliemo, Caterina del Mar Bonnin, Christopher Bowie, Vicent Balanza-Martinez, Katherine E. Burdick, Andre Carvalho, Annemieke Dols, Katie M. Douglas, Peter Gallagher, Lars V. Kessing, Beny Lafer, Kathryn E Lewandowski, Carlos Lopez-Jaramillo, Anabel Martinez-Aran, Roger S. McIntyre, Richard J. Porter, Scot E Purdon, Ayal SchafferPaul Stokes, T Sumiyoshi, Ivan J. Torres, Thamsyn Van Rheenen, Lakshmi N. Yatham, Allan Young, Eduard Vieta, Gregor Hasler

Research output: Contribution to journal › Review article › peer-review

1 Citation (Scopus)

Fingerprint

Dive into the research topics of 'Efficacy and safety of established and off-label ADHD drug therapies for cognitive impairment or attention-deficit hyperactivity disorder symptoms in bipolar disorder: A systematic review by the ISBD Targeting Cognition Task Force'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science